الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Background/Aim: Cisplatin, which is used to treat solid tumors , In spite of its significant anticancer activity, the clinical use is often limited by its undesirable side effects such as hepatotoxicity. The aim of this study was to evaluate protective effect of kinetin against Cisplatin induced hepatotoxicity.
Methods: Fifty four wistar male albino rats were divided into nine groups: (i) the control (C), (ii) groups 2,3 and 4, which received 0.25, 0.5 and 1 mg/kg kinetin for 10 days; (iii) the cisplatin (Cis) group, which received a single intraperitoneal injection of Cis (7.0 mg/kg); and (iv) groups 6, 7, 8 and 9, which received, for 10 days, 0.25, 0.5 and 1 mg/kg kinetin or 200 mg/kg vitamin C, respectively, and Cis on the fourth day. After ten days (the period of the experiment), rats were anesthetized using diethyl ether and before sacrificing; blood samples were collected, and serum samples were prepared. In addition, liver tissue samples were collected for the histopathological, biochemical and PCR analyses.
Result: Cisplatin-injected rats showed a significant impairment in biochemical, oxidative stress, inflammatory and apoptotic parameters in hepatic tissue .Concomitant administration of kinetin with cisplatin significantly restored the biochemical, redox status, Inflammatory, apoptosis parameters and histological changes.
Conclusion: Kinetin mitigated oxidative imbalance, inflammation and apoptosis in Cisplatin-induced liver toxicity; therefore, it can be considered as a promising therapy.